Per-protocol survival improved versus earlier cutoffs, with 35% alive beyond 30 months and 13% beyond 50 months after two ...

BobcatBio brought on the contract development and manufacturing organization to support manufacturing for ongoing Phase I studies in lymphoma and solid tumors.

Risankizumab produces rapid and sustained clinical remission and meaningful endoscopic outcomes through 52 weeks, with a favorable safety profile.

The Shenzhen, China-based biotech plans to launch a Phase I trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of IN026.

Title: First-in-human phase I study of PLN-101095, a first-in-class dual α v β 8 /α v β 1 integrin inhibitor, as monotherapy and in combination with pembrolizumab in patients with advanced solid ...

HONG KONG SAR, China and SHENZHEN, China and CAMBRIDGE, Mass., March 17, 2026 /PRNewswire/ -- Innorna, a clinical‑stage biotech company advancing RNA medicines, today announced that the U.S. Food and ...

HONG KONG SAR, China and SHENZHEN, China and CAMBRIDGE, Mass., March 17, 2026 /PRNewswire/ -- Innorna, a clinical--stage biotech company advancing RNA medicines, today announced that the U.S. Food and ...

Survival in myeloma is clearly being prolonged,” says Mikhael. “Whereas historically, we saw a greater impact in younger ...

Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough On track ...

Rapport Therapeutics, Inc. ( RAPP) Stifel 2026 Virtual CNS Forum March 17, 2026 9:30 AM EDT Great. Good morning, everybody. Happy to be here, moderating this panel with Abe Ceesay, CEO of Rapport ...

A DR5-mediated apoptotic strategy combined with irinotecan/temozolomide achieved a 64.5% ORR and 87.1% DCR in ...

A qualitative analysis explored how patients with hematopoietic malignancies seek meaning-making through relationships with family and friends at the end of life.